Abhishek is currently an assistant professor (BOF-ZAP) at KU Leuven, Belgium since Oct'2018 and heading the CSI Lab since Feb'2020. He has several years of experience in cellular and molecular immunology (e.g. danger signals, chemokines, phagocytosis and myeloid or lymphocytic phenotypes), cancer cell death & stress responses (e.g. immunogenic cell death/ICD, ER stress, autophagy, apoptosis, necroptosis), and cancer immunology & immunotherapy (e.g. anticancer vaccines including dendritic cell/DC vaccines, tumour-based immune-biomarkers). During his PhD, he performed front-line research on damage-associated molecular patterns (DAMPs) and ICD in cancer. Thereafter he continued as a postdoctoral researcher at KU Leuven, where he pursued studies on various immunological determinants of ICD and ICD-based DC vaccines. During his postdoc, he also carried out research visits to the University of Helsinki (Finland) and De Duve Institute (Belgium) to work on different aspects of cancer cell-innate immune cell interface and the interaction of antigen-specific T-cells with cancer cells, respectively. As head of the CSI Lab, his overarching vision is to exploit state-of-the-art reverse translational approaches (human to in vitro/in vivo & back), to facilitate translational immuno-oncology and enable successful transition of novel immunological concepts from benchside research to bedside reality.
Abhishek is currently an assistant professor (BOF-ZAP) at KU Leuven, Belgium since Oct'2018 and heading the CSI Lab since Feb'2020. He has several years of experience in cellular and molecular immunology (e.g. danger signals, chemokines, phagocytosis and myeloid or lymphocytic phenotypes), cancer cell death & stress responses (e.g. immunogenic cell death/ICD, ER stress, autophagy, apoptosis, necroptosis), and cancer immunology & immunotherapy (e.g. anticancer vaccines including dendritic cell/DC vaccines, tumour-based immune-biomarkers). During his PhD, he performed front-line research on damage-associated molecular patterns (DAMPs) and ICD in cancer. Thereafter he continued as a postdoctoral researcher at KU Leuven, where he pursued studies on various immunological determinants of ICD and ICD-based DC vaccines. During his postdoc, he also carried out research visits to the University of Helsinki (Finland) and De Duve Institute (Belgium) to work on different aspects of cancer cell-innate immune cell interface and the interaction of antigen-specific T-cells with cancer cells, respectively. As head of the CSI Lab, his overarching vision is to exploit state-of-the-art reverse translational approaches (human to in vitro/in vivo & back), to facilitate translational immuno-oncology and enable successful transition of novel immunological concepts from benchside research to bedside reality.